Key result
Supra-annular TAVR valves are linked to ~6.6-fold higher risk of unfeasible coronary access after TAVR-in-TAVR.
Why the study?
Displaced leaflets of a first THV create a risk plane during TAVR-in-TAVR below which coronary catheter passage is impossible, creating an unknown risk of impaired coronary access.
Does transcatheter heart valve design (supra-annular vs intra-annular) and aortic root anatomy affect the predicted feasibility of coronary access after TAVR-in-TAVR in patients undergoing native TAVR?
Cohort (n=137)
No
Does transcatheter heart valve design (supra-annular vs intra-annular) and aortic root anatomy affect the predicted feasibility of coronary access after TAVR-in-TAVR in patients undergoing native TAVR?
Coronary access after redo TAVR (TAVR-in-TAVR) is predicted to be unfeasible in nearly one-third of current TAVR patients, particularly women, those with a narrow sinotubular junction, and recipients of supra-annular valves, which should inform initial prosthesis selection in younger patients.
Answers are grounded in this paper and cite their sources.
May inform valve selection in younger TAVR candidates; leaves open prospective validation of coronary access strategies.
Background Transcatheter aortic valve replacement (TAVR)‐in‐TAVR is a possible treatment for transcatheter heart valve ( THV ) degeneration. However, the displaced leaflets of the first THV will create a risk plane ( RP ) under which the passage of a coronary catheter will be impossible. The aim of our study was to evaluate the potential risk of impaired coronary access ( CA ) after TAVR ‐in‐ TAVR . Methods and Results We prospectively performed coronary angiography after TAVR with different THV s in 137 consecutive patients, looking where the catheter crossed the valve frame. If coronary cannulation was achieved from below the RP , the distance between valve frame and aortic wall was measured by aortic angiography. CA after TAVR ‐in‐ TAVR was defined as feasible if the catheter passed above the RP , as theoretically feasible if passed under the RP with valve‐to‐aorta distance >2 mm, and as unfeasible if passed under the RP with valve‐to‐aorta distance ≤2 mm. Seventy‐two patients (53%) received a Sapien 3 THV, 26 (19%) received an Evolut Pro/R THV, and 39 (28%) received an Acurate Neo THV . CA after TAVR ‐in‐ TAVR was considered feasible in 40.9% (68.1%, 19.2%, and 5.1%, respectively; P <0.001), theoretically feasible in 27.7% (8.3%, 42.3%, and 53.8%, respectively; P <0.001), and unfeasible in 31.4% (23.6%, 38.5%, and 41.1%, respectively; P =0.116). Independent predictors of impaired CA after TAVR ‐in‐ TAVR were female sex (odds ratio [OR], 3.99; 95% CI , 1.07–14.86; P =0.040), sinotubular junction diameter (OR, 0.62; 95% CI , 0.48–0.80; P <0.001), and implantation of a supra‐annular THV (OR, 6.61; 95% CI , 1.98–22.03; P =0.002). Conclusions CA after TAVR ‐in‐ TAVR might be unfeasible in >30% of patients currently treated with TAVR . Patients with a small sinotubular junction and those who received a supra‐annular THV are at highest risk of potential CA impairment with TAVR ‐in‐ TAVR .
No takes yet. Share an insight, caveat, or question.
Fovino et al. (2020) conducted a cohort in Severe symptomatic aortic stenosis undergoing transcatheter aortic valve replacement (TAVR) (n=137). Supra-annular transcatheter heart valve (Evolut R/Pro or Acurate Neo) vs. Intra-annular transcatheter heart valve (Sapien 3/Ultra) was evaluated on Predicted unfeasibility of coronary access after TAVR-in-TAVR (coronary cannulation below the risk plane with valve-to-aorta distance ≤2 mm) (OR 6.61, 95% CI 1.98-22.03, p=0.002). Supra-annular TAVR valves independently increased the risk of unfeasible coronary access after future TAVR-in-TAVR, which was unfeasible in 31.4% overall.
Synapse has enriched 10 related papers. Consider them for comparative context: